Malaria

– R&D collaboration to deliver a new single, fixed-dose combination therapy, significantly increasing the potential to treat patients in endemic countries – Sanofi announced today that the company will extend its collaboration with Medicines for […]

Presented today (November 4) at the 63rd annual meeting of the American Society of Tropical Medicine and Hygiene (ASMTH), results of a multi-centre clinical trial in Africa, launched in 2008, to test the efficacy and tolerability of […]

Sanofi (EURONEXT: SAN and NYSE: SNY) announced on World Malaria Day that 300 million treatments of anti-malarial ASAQ Winthrop® have been delivered in Africa since the medication became available in 2007. “Beyond the therapeutic and […]

The World Health Organization and other development partners have stepped up efforts to vaccinate people against the outbreak of measles and other preventable diseases at displaced camps in South Sudan. This follows tests which confirmed […]

Aujourd’hui, les cadres dirigeants de Novartis se réunissent à Bâle, en Suisse, à l’occasion du premier « Novartis Africa Day ». Ils passeront en revue le travail mené par l’entreprise en Afrique, notamment l’activité commerciale croissante, les […]

Heute treffen sich Führungsverantwortliche von Novartis in Basel, Schweiz, für den ersten Novartis Africa Day. Sie werden dort die innovative Arbeit des Unternehmens in Afrika prüfen, insbesondere die wachsenden kommerziellen Aktivitäten, neuartige Ansätze für einen […]

Today, Novartis senior executives gather in Basel, Switzerland for the first-ever Novartis Africa Day, to review the company’s innovative work in Africa, including growing commercial activity, novel approaches to expand access to high-quality, affordable medicines, […]

Les chercheurs de Novartis ont découvert une nouvelle cible médicamenteuse pour le traitement du paludisme. La découverte, publiée en ligne dans la revue Nature,[2] identifie phosphatidylinositol-4-kinase (PfPI4K) comme cible des imidazopyrazines, une nouvelle classe de […]